Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Anju Ghangurde
Glenmark-Celon’s generic Seretide Accuhaler dry powder inhaler (DPI) has hit the Danish market but whether it can build momentum around its regulatory clearance for substitution remains to be seen.
Lupin ended the fourth quarter in the red hit by an impairment provision related to the "underperforming" assets of its Gavis acquisition but the firm's US inhalation pipeline appears to have made some progress, including a filing for tiotropium dry powder inhaler (DPI). Early stage biosimilars under development include, among others, versions of Neulasta and Xgeva/Prolia.
Eli Lilly's Taltz (ixekizumab) may be staring at stretched launch timelines in India where competitor secukinumab already has a head start, after the US company's request for a local trial waiver for the product was turned down twice.
Are drug firms being lax when it comes to Phase IV studies in markets like India or are certain arbitrarily determined regulatory requirements largely to blame? Scrip delves into the issue.
Cipla is to commercialize the financially troubled MannKind’s inhaled insulin Afrezza in India, but it remains to be seen whether the deal can materially change the fortunes of the product.